IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
165
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Gastric Cancer
Gastroesophageal-junction Cancer
Interventions
DRUG:
IKS014
Sponsor
Iksuda Therapeutics Ltd.